Trials / Completed
CompletedNCT00725543
Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)
Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 358 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time span of Remicade between infusions for ankylosing spondylitis (AS).
Detailed description
This study population was chosen from a non-probability sample.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infliximab | Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians. |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-07-30
- Last updated
- 2015-09-30
- Results posted
- 2011-07-07
Source: ClinicalTrials.gov record NCT00725543. Inclusion in this directory is not an endorsement.